Business Wire

The Rise of 3D Scanning: Revopoint POP Launch

3.2.2021 11:37:00 EET | Business Wire | Press release

Share

Recently, a Kickstarter campaign for Revopoint POP 3D scanner has raised more than US$2 million from more than 5,700 backers as of press time. It makes Revopoint POP a "history-making 3D scanner" both in terms of the amount of money raised and the number of backers. Of course, Revopoint POP is not the first 3D scanner to be successfully funded through a crowdfunding platform. Historically, outstanding results included C$651,091 for PeachyPrinter in 2016 and US$599,925 for Eora3D in 2018. To add to it, the crowdfunding campaign for Revopoint POP is not over yet, which means the support and trust from people across the globe will keep growing stronger.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210203005350/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

POP is a consumer-grade high-precision 3D scanner developed by experts at Revopoint from Shenzhen. Compared to existing products in the market, POP has the advantages of high precision and low power consumption while offering an affordable price. Simultaneously, it has multi-terminal coverage, i.e., it can be used with mobile phones, notebooks, or computers, making it user-friendly.

As a representative revolutionary technology in the manufacturing field, 3D printing has been gradually receiving more attention. Since the invention of affordable household 3D printers, millions of them have entered consumers' homes every year and have become scorching property. However, the challenging part for 3D printing remains to be 3D modeling. Therefore, precise 3D scanning is a perfect starting point for 3D printing creativity. Besides, 3D scanners can also be used for customized product design, cultural relic conservation, VR/AR, and other applications. Hence an affordable, precise, and handy 3D scanner like Revopoint POP could very well be the next big thing.

Mr. Hassan Iftikhar, a product design researcher from the School of Design, Hong Kong Polytechnic University, recently designed customized facial personal protective gear for protection during the COVID-19 pandemic, using 3D scans acquired from the POP scanner. This is one of the best examples of how 3D scanners like POP can address everyday challenges using 3D scanning technology.

As the age of 3D printer has arrived, the future of 3D scanners is coming. Such a grand success of this crowdfunding campaign may well pave the road for promoting similar 3D scanners. I believe that ordinary consumers like you and me will get to know shortly.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Revopoint 3D Technologies Inc.
https://www.revopoint3d.com/
Andy Yang
andy@revopoint3d.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 15:00:00 EET | Press release

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc

Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 15:00:00 EET | Press release

Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Esri’s geospatial platform. Field teams use the PIX4Dcatch app with real-time kinematics (RTK) devices to scan trenches and infrastructure. The generated high precision georeferenced records can now be published into Esri’s ArcGIS Online. Scans become 3D models and point clouds, viewable as a Scene Layer. Existing data can also be visualized in augmented reality for instant “as-designed” versus “as-built” verification before closing trenches. “We are focused on turning hidden infrastructure into functional data,” said Andrey Kleymenov, CEO of Pix4D. “By connecting PIX4Dcatch with a compatible RTK device to the Esri ecosystem, we are enab

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6. Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint. Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (

BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 13:00:00 EET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the

CTC Global Launches GridVista System and Strategic Partnership with Google Cloud and Tapestry to Transform Grid Intelligence17.2.2026 13:00:00 EET | Press release

CTC Global, the world’s leading developer and manufacturer of high-capacity advanced conductors, today announced the launch of the GridVista System. The GridVista System provides utilities with real-time, high-resolution data to optimize grid capacity, prevent outages, reduce wildfire risk, and lower operational costs. With the launch of the GridVista System, CTC is also announcing a deepening of its strategic partnership with Google Cloud and Tapestry—Alphabet’s moonshot for the electric grid. GridVista System’s unprecedented line awareness, paired with Google Cloud and Tapestry’s AI-powered tools, will transform line data into actionable intelligence for the grid. The GridVista System redefines transmission line intelligence by utilizing optical fibers embedded directly within CTC Global’s ACCC Conductor. Unlike legacy technology that relies on external sensors to estimate line conditions, GridVista provides direct visibility into strain, temperature, and vibration across the entire

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye